Key result
Transgenic SQT1 rabbits exhibit ~19 ms shorter QT intervals and increased VT/VF inducibility versus wild-type.
Why the study?
Short-QT syndrome 1 is an inherited channelopathy with variable phenotype causing arrhythmias and sudden cardiac death, requiring a model to study its mechanisms and treatments.
Absolute Event Rate: 147.8% vs 166.4%
p-value: p=<0.0001
Transgenic SQT1 rabbits successfully mimic the human short-QT syndrome phenotype, including shortened QT/APD and increased VT/VF inducibility, and show beneficial responses to quinidine.
SQT1 rabbit model replicates shortened QT and higher VT/VF risk; leaves open translation to human therapy.
AIMS: Short-QT syndrome 1 (SQT1) is an inherited channelopathy with accelerated repolarization due to gain-of-function in HERG/IKr. Patients develop atrial fibrillation, ventricular tachycardia (VT), and sudden cardiac death with pronounced inter-individual variability in phenotype. We generated and characterized transgenic SQT1 rabbits and investigated electrical remodelling. METHODS AND RESULTS: Transgenic rabbits were generated by oocyte-microinjection of β-myosin-heavy-chain-promoter-KCNH2/HERG-N588K constructs. Short-QT syndrome 1 and wild type (WT) littermates were subjected to in vivo ECG, electrophysiological studies, magnetic resonance imaging, and ex vivo action potential (AP) measurements. Electrical remodelling was assessed using patch clamp, real-time PCR, and western blot. We generated three SQT1 founders. QT interval was shorter and QT/RR slope was shallower in SQT1 than in WT (QT, 147.8 ± 2 ms vs. 166.4 ± 3, P < 0.0001). Atrial and ventricular refractoriness and AP duration were shortened in SQT1 (vAPD90, 118.6 ± 5 ms vs. 154.4 ± 2, P < 0.0001). Ventricular tachycardia/fibrillation (VT/VF) inducibility was increased in SQT1. Systolic function was unaltered but diastolic relaxation was enhanced in SQT1. IKr-steady was increased with impaired inactivation in SQT1, while IKr-tail was reduced. Quinidine prolonged/normalized QT and action potential duration (APD) in SQT1 rabbits by reducing IKr. Diverse electrical remodelling was observed: in SQT1, IK1 was decreased-partially reversing the phenotype-while a small increase in IKs may partly contribute to an accentuation of the phenotype. CONCLUSION: Short-QT syndrome 1 rabbits mimic the human disease phenotype on all levels with shortened QT/APD and increased VT/VF-inducibility and show similar beneficial responses to quinidine, indicating their value for elucidation of arrhythmogenic mechanisms and identification of novel anti-arrhythmic strategies.
No takes yet. Share an insight, caveat, or question.
Odening et al. (2018) studied Short-QT syndrome 1 (SQT1). Transgenic SQT1 model (HERG-N588K) vs. Wild type (WT) littermates was evaluated on QT interval (ms) (p=<0.0001). Transgenic SQT1 rabbits exhibited a significantly shorter QT interval compared to wild type littermates (147.8 vs 166.4 ms, P<0.0001) and increased VT/VF inducibility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: